Technology transfer significance in IP MCQs With Answer

Introduction

Technology transfer significance in IP MCQs With Answer is a focused quiz tailored for M.Pharm students to deepen understanding of how technology transfer intersects with intellectual property in pharmaceutical development. Technology transfer is not only about replicating a process but securing and communicating critical know‑how, data, and regulatory documentation while protecting proprietary assets. This set of MCQs covers core concepts such as patents, trade secrets, confidentiality agreements, licensing, validation during scale‑up, documentation requirements, freedom‑to‑operate, and regulatory implications. The questions emphasize practical scenarios encountered during CMC, process validation, and post‑approval changes to prepare students for industry roles involving both technical transfer and IP stewardship.

Q1. What is the primary IP concern during pharmaceutical technology transfer from R&D to manufacturing?

• Ensuring transfer of raw materials specifications
• Protecting proprietary know‑how and trade secrets
• Minimizing production costs
• Obtaining additional clinical data

Correct Answer: Protecting proprietary know‑how and trade secrets

Q2. Which agreement is most commonly used to prevent disclosure of confidential information during technology transfer?

• Material Transfer Agreement (MTA)
• Confidentiality or Non‑Disclosure Agreement (CDA/NDA)
• Supply Contract
• Clinical Trial Agreement

Correct Answer: Confidentiality or Non‑Disclosure Agreement (CDA/NDA)

Q3. In the context of patents and technology transfer, “freedom to operate” means:

• Ability to scale up manufacturing without equipment limits
• Assurance that a product or process can be used commercially without infringing existing patents
• Permission from the regulator to market the product
• Access to contract manufacturers

Correct Answer: Assurance that a product or process can be used commercially without infringing existing patents

Q4. Which document outlines the specific steps, analytical methods, and acceptance criteria to be transferred?

• Technology Transfer Protocol (TTP)
• Quality Manual
• Marketing Authorization
• Clinical Study Report

Correct Answer: Technology Transfer Protocol (TTP)

Q5. During transfer, validation activities are important primarily to:

• Reduce raw material cost variability
• Demonstrate reproducibility and equivalence of process and product at the receiving site
• Ensure faster time to market irrespective of quality
• Document marketing strategies

Correct Answer: Demonstrate reproducibility and equivalence of process and product at the receiving site

Q6. Which IP protection is best for process steps and formulations that are not publicly disclosed?

• Patent with full public disclosure
• Trade secret protection
• Trademark registration
• Copyright registration

Correct Answer: Trade secret protection

Q7. A Material Transfer Agreement (MTA) is primarily used to:

• Protect market exclusivity through patent filing
• Define terms for sharing biological or chemical materials between parties
• Establish clinical endpoint definitions
• Set pricing for bulk drug supply

Correct Answer: Define terms for sharing biological or chemical materials between parties

Q8. Which of the following is a common IP risk when outsourcing manufacturing during technology transfer?

• Loss of drug stability
• Unintentional disclosure of proprietary methods to third parties
• Faster regulatory approvals
• Improved batch yields

Correct Answer: Unintentional disclosure of proprietary methods to third parties

Q9. For regulatory filings, how should IP‑sensitive CMC data be handled during technology transfer to avoid compromising patents?

• Never include any process details in regulatory submissions
• Use redacted or limited public dossiers while providing full data to regulators under confidentiality
• Publish all details in peer‑reviewed journals
• Delay filing until patents expire

Correct Answer: Use redacted or limited public dossiers while providing full data to regulators under confidentiality

Q10. When assessing a potential licensee in technology transfer, which IP due diligence activity is essential?

• Reviewing the licensee’s advertising budget
• Evaluating the licensee’s patent portfolio and freedom‑to‑operate landscape
• Checking the licensee’s clinical trial sites
• Assessing the geographical reach of the licensee’s sales team

Correct Answer: Evaluating the licensee’s patent portfolio and freedom‑to‑operate landscape

Q11. Which strategy helps protect proprietary process parameters during scale‑up in a transferred process?

• Disclosing every detailed parameter to vendor staff
• Using encrypted data rooms and limiting access to essential personnel
• Publishing parameters in patent applications without claims
• Outsourcing to multiple small vendors without agreements

Correct Answer: Using encrypted data rooms and limiting access to essential personnel

Q12. What role does a competency assessment of receiving site personnel play in technology transfer related to IP?

• It determines marketing claims for the product
• Ensures personnel understand critical control points and confidentiality obligations
• Is used to negotiate royalty rates
• Lists the equipment costs for regulatory filings

Correct Answer: Ensures personnel understand critical control points and confidentiality obligations

Q13. In the event of IP infringement discovered after transfer, the first appropriate action is to:

• Immediately halt all production without assessment
• Conduct a legal and technical investigation including comparing claims and supply chain practices
• Publicly disclose the infringement on social media
• Ignore it if batches meet specifications

Correct Answer: Conduct a legal and technical investigation including comparing claims and supply chain practices

Q14. Which element in a technology transfer file has dual importance for validation and IP protection?

• Sales forecasts
• Detailed process flow diagrams and critical process parameters
• Employee benefits information
• Vendor marketing material

Correct Answer: Detailed process flow diagrams and critical process parameters

Q15. Licensing agreements in pharma technology transfer commonly include clauses for:

• Clinical efficacy endpoints decisions
• Scope of IP rights, royalties, confidentiality, and quality obligations
• Advertising creative control
• Medical curriculum content

Correct Answer: Scope of IP rights, royalties, confidentiality, and quality obligations

Q16. Which regulatory concept ensures that a transferred product remains comparable to the original after site change?

• Bioequivalence waiver
• Comparability assessment and bridging studies
• Marketing exclusivity extension
• Patent arbitration

Correct Answer: Comparability assessment and bridging studies

Q17. How can patents facilitate technology transfer rather than hinder it?

• By making processes freely usable by any manufacturer
• By licensing protected technologies under defined terms, enabling controlled transfer
• By preventing any form of know‑how sharing
• By eliminating the need for NDAs

Correct Answer: By licensing protected technologies under defined terms, enabling controlled transfer

Q18. Which practice best preserves data integrity while sharing electronic validation records during transfer?

• Allowing unrestricted downloads to personal devices
• Using secure audit‑trail enabled systems and role‑based access
• Printing and faxing confidential logs to third parties
• Uploading to public cloud without controls

Correct Answer: Using secure audit‑trail enabled systems and role‑based access

Q19. During post‑approval technology transfer, what IP‑related concern must be addressed when changing suppliers of a critical raw material?

• Whether the new supplier’s packaging is superior
• Compatibility with existing patents and potential necessity for new patent licenses or notices
• Supplier’s cafeteria menu
• The supplier’s proximity to headquarters

Correct Answer: Compatibility with existing patents and potential necessity for new patent licenses or notices

Q20. What is the best practice for transferring proprietary analytical methods while protecting IP?

• Provide only summary results without method details
• Transfer method SOPs under NDA and provide hands‑on training with limited disclosure of proprietary rationale
• Publish full method in an open database
• Share method details with all subcontractors globally without agreements

Correct Answer: Transfer method SOPs under NDA and provide hands‑on training with limited disclosure of proprietary rationale

Download